Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Results due this month and should show the increased turnover as promised,
“A significant increase in contracted annual recurring revenues ("ARR"), a key metric for the business, is expected to be delivered, with ARR for the full year of c. £15m (2021: £1.8m). Following upgraded market expectations adjusted EBITDA was at a breakeven level (2021 EBITDA loss: £4.1m) and net cash at 31 March 2022 was £7.5m (2021: £2.4m)”.
So these results are already six months old.
Pinning my hopes on an outstanding update on trading, which could move the price up quite quickly, with any luck :-)
Looks rather promising to me
did say this would head up.
boom!
up she goes
Thanks for sharing Rich. I would have thought it would make a move back up towards the 70p area in the short term at the very least.
I've been watching and holding for over a year now.
With much good news the sp seems to have stagnated/dropped.
Long term hold for me until I see a good return.
Too far underwater to sell and I am optimistic that the product will take off big time in the very near future.
Anyone else watching this?
Things are getting interesting here.
I expected M&As as that's how they gain new features etc... so this is great news overall. We now have a breakeven time frame which might bring in more institutional investors.
The 70p placing seems heavily discounted, so a bit annoyed as a current shareholder, though if I'm offered shares I'll buy them at that price. With how low the volume is of share buying/selling the new shares might all go to institutional investors as for an institution to build a decent holding on the open market might be impossible short-term.
I have some detailed research on INHC on my free to join Discord server: https://discord.gg/8TDWN25YjY
Hello. Looking at the prospects for this company, it seems like a good business, with revenue starting to flow and a big backlog of non-Covid work making the future seem bright. Recurring revenue gives long term potential. The recent proposal though, is a massive leap in growth for a small enterprise, making it a big risk/reward bet in the short term. How do current investors feel about the placing at 70p ?
jc1220 Good question.
I haven't researched the competition in enough detail to say INHC is THE one, but what made the investment decision an easy one for me was Drs have already made the choice, they use their apps.
It means when INHC adds another service/upgrades etc... the Drs (the users) will know it exists and some of those Drs are involved in making decisions on what an NHS trust uses in the future.
They haven't reinvented the wheel here to try to break into a market, they've seen what the NHS etc... is using and acquired the app.
There's going to be a lot of trusts who currently don't have a service anywhere near as good as what INHC offers and with them building a suite of complimentary apps with some already the best app available (best based on how many Drs use them), seems like they could build serious traction long-term.
Hi all
Just started my research into this company. Sounds really promising but I'm curious about the competition.
Why would a hospital / medical centre choose Induction's products over the other ~23 on the NHSX clinical communications procurement list? What would prompt them to switch service and what makes you confident in INHC's market penetration?
Without being a doctor or nurse I feel almost blind as to how the market operates and therefore what the growth potential of the company is. The one thing I am confident in is how slow and bureaucratic the NHS can be - which does not fill me with short term confidence. Any knowledge share would be appreciated.
bought this at 52 week lows. Only positive news since.
Wish i had put my life savings in this.
Some serious investors behind it and will move up at it's own place as and when new contracts are signed. Very Promising share to be in, hold long and strong.
Positive RNS early today. Covid-stock hunters will no doubt zero-in on the contracts with University of the West of England (UWE) and South Gloucestershire Council (SGC) for the booking of Covid-19 Lateral Flow Tests (LTFs). It's really interesting the Board has only just made this announcement when INHC's tech was in fact being used back in Christmas - this suggests to me there might be other product developments and contracts going on which we may only learn of when the Board releases a Trading Update (possibly in April) or the Full Year Report (possibly in June).
I would encourage investors to look past the Covid-news though. The UWE and SGC contracts are great, the deployment of Induction Switch at Nightingale Hospitals is also positive. But INHC is working on so much more than Covid related products.
Flagship product Induction Switch is a smartphone-based messaging tool which conforms to NHS patient information sharing guidelines and has significant market penetration: the Board states more than half of UK doctors use the app. The app has several user levels: L0, L1, L2, and L3. L0 and L1 are free to use. L2 and L3 are paid for by the institution.
INHC has other products too. Microguide is an app-based resource used by doctors and GPs as reference for subjects like antimicrobial resistant bacteria. Zesty is an online platform/portal that has recently teamed up with NHS tech-supplier Cerner and Apple to provide patients at Milton Keynes Hospital with access to and control of their medical information.
Of course I am summing up these products, there is so much more to them than what I can write here.
The Board is made up of the same team that built and sold the successful DrugDev platform. And it's worth noting that a whopping 80% of INHC shares are held by the Board or Institutions (33% owned by Directors in fact, talk about skin in the game). I expect the time for marketing the company to investors will come in the not too distant future, but in the meantime the Board seems to be busy building their products.
I've spent these past few weeks building my position here as I anticipate the company will be flying within the next 12 months and do even better in the years ahead. I encourage other readers to conduct your own research on INHC, you may well then understand why I am so bullish on the company.
This stock is so unnoticed by PIs, volume is non-existent!
It's a tech stock with NHS contracts & looks like it's a only matter of time before there's a cascade of NHS hospitals signing up.
Bought 5,000 shares today for a long-term hold.
Cya in 6 months :-)
Oops, it doesn't like my typing. Cash at end March £10.7m. Cash at end Sept £5.0m.
"Robust balance sheet, with net cash of £5.0 million; prudent management of costs and cashflow"
Cash at 31.03.20 £10.7m. Cash at 30.09.20 £5.0m.
Cash burn from Ops £5.0m pa.
Crikey.
After the year we have had this is a really pleasijg summary of Financials.
First full year of revenue
· Strong momentum in sales and Annual Recurring Revenue (ARR) run rate across all its subscription-based software products
· Revenues of £0.6m, includes first revenue generated by Induction Switch (as previously indicated)
· Robust balance sheet, with net cash of £5.0 million; prudent management of costs and cashflow
· Deferred revenue at £0.6m (H1 2020: nil)
The Induction Switch App has some solid user reviews. INHC is not just about his app though, it seems like Board are building up a portfolio of channels and apps.
I agree with Khun that this is under the radar, possibly at the behest of the Board as it seems they want to be going about their business without much attention right now.
I think MicroGuide is the only revenue generating product at the moment. Induction Switch was added to NHSX recently so it may start to generate some revenue but would not imagine it to be too much right now.
If Board is to be believed, Switch App has proliferated through NHS staff. However these users are not paying for use. Question for INHC is how can this App (and others) be monetised? Will it be user subscription? Will it be institutional procurement? Perhaps an advertising model (unlikely in my opinion)? Or a combination of these ideas and/or others.
For those who want to get into INHC, my feeling is this will be a long term hold. Find an agreeable price to buy in (currently INHC trading at roughly 30% discount to its IPO price 18 months ago) and then forget about it for a couple years while platforms are developed and new channels are acquired.
I'm trying to buy through HSBC but with no joy. Am I missing something here, all recent trades are listed as off-book?
Some big buys yesterday potential news on the way